Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies

• US 4,938,948 A
• Filed: 10/11/1985
• Issued: 07/03/1990
• Est. Priority Date: 10/07/1985
• Status: Expired due to Fees

• Current Assignee: Chiron Corporation (Bayer AG)
• Original Assignee: Cetus Corporation (Bayer AG)
• Inventors: Frankel, Arthur E., Ring, David B.
• Primary Examiner(s): Rosen, Sam
• Application Number:
  US06/786,948
• Time in Patent Office: 1,726 Days
• Field of Search: 435/7, 435/172.1, 435/172.2, 435/240, 436/547, 436/548, 424/9, 424/4
• US Class Current: 424/1.53
• CPC Class Codes: A61K 49/0058 Antibodies
• CPC Class Codes: A61K 51/10 Antibodies or immunoglobulins; Fragments thereof , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
• CPC Class Codes: A61K 51/1093 conjugates with carriers being antibodies
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: Y10S 424/804 involving IgG3, IgG4, IgA, or IgY
• CPC Class Codes: Y10S 424/807 Monoclonal
• CPC Class Codes: Y10S 435/948 using viruses or cell lines
• CPC Class Codes: Y10S 530/808 Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
• CPC Class Codes: Y10S 530/861 involving IgG3, IgG4, IgA, or IgY

Abstract

Hybridomas producing monoclonal antibodies suitable for imaging and diagnosis of human breast tumors and such monoclonal antibodies are claimed. The monoclonals are characterized by breast tumor binding range, breast cancer cell line range, and selectivity.

Immunoimaging agents comprising the monoclonal antibody and a detectable label, either directly or indirectly conjugated to the antibody are claimed. Methods for imaging breast tumors using the immunoimaging agents are described and claimed.

Claims

1. A method for imaging breast tumors, comprising the steps of:

(a) producing an immunoimaging composition comprising covalently binding an imaging moiety to a murine monoclonal antibody suitable for imaging breast tumors, said murine monoclonal antibodies having the properites of not binding to blood cells or human mammary tumor virus, a breast tumor binding range of at least 0.25, or has a breast cancer cell line range of greater than or equal to 0.25, a selectivity equal to or less than 0.09, a G or M isotype, and are selected from the group consisting of 2G3, 9C6, 32A1, 35E10, 87H7, 106A10, 120H7, 140A7, 260F9, 203E2, 219F3, 452E12, 454A12, 650E2, 697B3, 759E3, and 788G6;

(b) administering said imaging composition to a patient; and

(c) detecting a signal produced by said imaging moiety.

2. The method as described in claim 1, wherein said detectable imaging moiety is bound to said monoclonal antibody using N-chloro-p-toluenesulfonamide or tetrachloro-3α

, 6α

-diphenylglycouril.

3. The method as described in claim 2, wherein said imaging moiety is bound to a linker that is bound to said monoclonal antibody.

4. The method as described in claim 3, wherein said linker is methyl-p-hydroxybenzimidate or N-succinimidyl-3-(4-hydroxyphenyl)propionate.

5. The method as described in claim 4, wherein said imaging moiety is bound to said murine monoclonal antibody by a chelating agent.

6. The method as described in claim 5, wherein said chelating agent is diethylenetriaminepentaacetic acid anhydride or ethylenetriaminetetraacetic acid.

7. The method as described in claim 6, wherein said imaging moiety is selected from the group consisting of:

(a) fluorochromes;

(b) radioactive iostypes;

(c) radiopaque substances; and

(d) NMR detectable substances.

8. The method as described in claim 7, wherein said radio isotope is selected from the group consisting of ¹²³ Iodine, ¹³¹ Iodine, ¹¹¹ Indium and ⁹⁹ Technetium.

9. The method as described in claim 2, wherein said imaging agent is administered to a patient with a carrier suitable for parenteral administration.